Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 1
2022 1
2023 4
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Belada D, et al. Among authors: persona ep. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. Blood. 2023. PMID: 37369099 Free PMC article. Clinical Trial.
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Dachs LR, Gaisán CM, Bustamante G, López SG, García EG, Persona EP, González-Calle V, Auzmendi MS, Pérez JMA, González Montes Y, Ríos Tamayo R, de Miguel Llorente D, Bernal LP, Mayol AS, Caro CC, Grande M, Fernández-Nistal A, Naves A, Miguel EMOS. Dachs LR, et al. Among authors: persona ep. Leuk Lymphoma. 2023 Nov-Dec;64(11):1847-1856. doi: 10.1080/10428194.2023.2240922. Epub 2023 Aug 4. Leuk Lymphoma. 2023. PMID: 37539698
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, Lluch R, Marrero C, Zudaire M, Gironella M, Hernández-Rivas JÁ, Arnan M, Olivier C, Encinas C, Soler JA, Payer ÁR, Casado A, Fernández P, Vilanova D, Bonanad S. de la Rubia J, et al. Among authors: persona ep. J Geriatr Oncol. 2023 Jan;14(1):101401. doi: 10.1016/j.jgo.2022.10.016. Epub 2022 Nov 18. J Geriatr Oncol. 2023. PMID: 36404260 Free article.
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.
Alegre A, Gironella M, Escalante F, Bergua JM, Martínez-Chamorro C, López A, González E, Bárez A, Somolinos N, Persona EP, Cabrera AS, Soler A, Rodríguez BI, López JM, González Y, Giménez VC, Sampol A, Muñoz C, Vilanova D, Durán M, Fernández de Larrea C; Spanish Myeloma Group (GEM_PETHEMA). Alegre A, et al. Among authors: persona ep. Hemasphere. 2024 Jul 4;8(7):e81. doi: 10.1002/hem3.81. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38974896 Free PMC article.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group. García-Marco JA, et al. Among authors: persona ep. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. Haematologica. 2019. PMID: 30890600 Free PMC article.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA; GABRIELL Study Group/Investigators. Bravo J, et al. Leuk Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. Epub 2023 May 31. Leuk Lymphoma. 2023. PMID: 37255002 Clinical Trial.